New drug duo takes on advanced bladder cancer in early trial
NCT ID NCT07636772
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called AK146D1, given alone or with another drug (AK112), in people with advanced urothelial carcinoma (a type of bladder cancer). The goal is to see if the treatment is safe and can shrink tumors. About 132 adults aged 18-75 with measurable tumors and good organ function may join.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood draw could spot bladder Cancer's return
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- A simple urine test could revolutionize bladder cancer detection
- Could a drug combo spare bladder cancer patients from surgery?
- New drug targets hard-to-treat cancers in early trial
- New hope for advanced HER2 cancers? drug trial launches